研究单位：[1]Akeso[2]The first affiliated hospital of bengbu medical college,Bengbu,Anhui,China,233099[3]Anhui provincial hospital,Hefei,Anhui,China,230001[4]Anhui provincial cancer hospital,Hefei,Anhui,China,230088[5]The first affiliated hospital of wannan medical college,Wuhu,Anhui,China,241001[6]Cancer hospital, Chinese academy of medical sciences and Peking union medical college,Beijing,Beijing,China,100021[7]The Fifth Medical Center of the Chinese People''s Liberation Army General Hospital,Beijing,Beijing,China,100039[8]Beijing Cancer Hospital,Beijing,Beijing,China,100142[9]Beijing Chest hospital,Beijing,Beijing,China,101149[10]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400030[11]Fujian cancer hospital,Fuzhou,Fujian,China,350014[12]Zhangzhou municipal hospital of fujian province,Zhangzhou,Fujian,China,363099[13]Gansu provincial cancer hospital,Lanzhou,Gansu,China,730050[14]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China,510080[15]Affiliated cancer hospital and institute of guangzhou medical university,Guangzhou,Guangdong,China,510095[16]Nanfang hospital,Guangzhou,Guangdong,China,510515[17]Cancer hospital Chinses academy of medical sciences， shenzhen center,Shenzhen,Guangdong,China,518172[18]Hainan cancer hospital,Haikou,Hainan,China,570312[19]Affiliated hospital of Hebei university,Baoding,Hebei,China,050031[20]The second people''s hospital of Hengshui,Hengshui,Hebei,China,053099[21]The Second Hospital of HeBei Medical University,Shijiazhuang,Hebei,China,050004[22]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050011[23]Tangshang people''s hospital,Tangshan,Hebei,China,063001[24]Harbin medical university cancer hospital,Harbin,Heilongjiang,China,150081[25]Jiamusi Tuberculosis Prevention and Control Hospital (Jiamusi Cancer Hospital),Jiamusi,Heilongjiang,China,154007[26]The first hospital of Qiqihar,Qiqihar,Heilongjiang,China,161005[27]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China,450052[28]Nanyang central hospital,Nanyang,Henan,China,473005[29]The First Affiliated Hospital of Xinxiang Medical College,Xinxiang,Henan,China,45310[30]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[31]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[32]Renmin Hospital of Wuhan University,Wuhan,Hubei,China,430060[33]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[34]Xiangya Hospital of Central South University,Changsha,Hunan,China,410008[35]The Second Xiangya Hospital, Central South University,Changsha,Hunan,China,410012[36]Hunan Cancer Hospital,Changsha,Hunan,China,410013[37]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006[38]The affiliated hospital of xuzhou medical university,Xuzhou,Jiangsu,China,221799[39]First Affiliated Hospital of Gannan medical college,Ganzhou,Jiangxi,China,341000[40]First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[41]The first hospital of Jilin Universit,Changchun,Jilin,China,130061[42]Tonghua Central Hospital,Tonghua,Jilin,China,134099[43]The First Hospital of China medical University,Shenyang,Liaoning,China,110002[44]Liaoning cancer hospital,Shenyang,Liaoning,China,110801[45]General hospital of ningxia medical university,Yinchuan,Ningxia,China,750003[46]Qinghai university affiliated hospital,Xining,Qinghai,China,810012[47]Binzhou medical university hospital,Binzhou,Shandong,China,256603[48]Shandong Cancer Hospital,Jinan,Shandong,China,250117[49]The Affiliated Hospital of Qingdao University,Qingdao,Shandong,China,266000[50]Weifang NO.2 people''s Hospital,Weifang,Shandong,China,261041[51]Zhongshan Hospital, Fudan university,Shanghai,Shanghai,China,200032[52]Changzhi people''s hospital,Changzhi,Shanxi,China,046099[53]Shanxi Cancer hospital,Taiyuan,Shanxi,China,0300
研究目的：
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS < 1%.
